 The National Medical Products Administration NMPA of China has signed off I-Mabs NASDAQ: IMAB IND application to initiate a Phase 2 trial of efineptakin alfa for advanced solid tumors. The trial will evaluate efineptakin alfa in combination with anti-PD-1 antibody for tumors, including triple-negative breast cancer and head and neck cancers HNC. 